Document:

EXHIBIT 10.13

 

Execution Version

  

VOTING
AGREEMENT

 

This
Voting Agreement (this “Agreement”) is made as of February 11, 2022, by and among Varian Biopharmaceuticals, Inc.,
a Florida corporation (the “Company”), SPK Acquisition Corp., a Delaware corporation (“Parent”),
Todd Wider (“Wider”), Keystone Capital Partners, LLC (“Keystone”), Paul E. Mann (“Mann”),
Jonathan Lewis (“Lewis”), Jeffrey B. Davis (“Davis”, and together with the Company, Wider, Keystone,
Mann, Davis and Lewis, the “Company Voting Parties” and each a “Company Voting Party,”), SPK Acquisition
LLC, a Delaware limited liability company (“the “Sponsor”), Justin Chang (“J. Chang”), Bryant
Chou (“Chou”), Chris Wenbing Wang (“Wang”), Greg Chang (“G. Chang”, and together
with Sponsor, J. Chang, Chon and Wang, the “Parent Voting Parties” and each a “Parent Voting Party,”
and the Parent Voting Parties together with the Company Voting Parties, the “Voting Parties” and each a “Voting
Party”). For purposes of this Agreement, capitalized terms used and not defined herein shall have the respective meanings ascribed
to them in the Merger Agreement (as defined below).

 

RECITALS:

 

WHEREAS,
the Company, Parent, and SPK Merger Sub, Inc., a Delaware corporation (“Merger Sub”) entered into a Merger Agreement,
dated as of the date hereof (the “Merger Agreement”);

 

WHEREAS,
pursuant to the Merger Agreement, Merger Sub will merge with and into the Company, after which the Company will be the surviving company
(“Surviving Corporation”) and a wholly-owned subsidiary of Parent and Parent shall change its name to “Varian
Biopharma, Inc.”;

 

WHEREAS,
each of the Voting Parties currently owns, or on closing of the transactions contemplated by the Merger Agreement, will own, shares of
the Parent’s capital stock, and wishes to provide for orderly elections of the Parent’s Board of Director’s (the “Parent
Board”) and Surviving Corporation’s Board of Directors (“Surviving Corporation’s Board”) as
described herein; and

 

WHEREAS,
the execution and delivery of this Agreement is a condition to the Closing and the other transactions contemplated by the Merger Agreement.

 

NOW
THEREFORE, in consideration of the foregoing and of the promises and covenants contained herein, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:

 

1.                           Agreement
to Vote. Each Voting Party shall vote all securities of Parent that may vote in the election of the Parent’s Board and Surviving
Corporation’s Board that such Voting Party owns from time to time (hereinafter referred to as the “Voting Shares”)
in accordance with the provisions of this Agreement, whether at a regular or special meeting of stockholders or any class or series of
stockholders or by written consent. 

    1

     

    

 

2.                           Election
of Parent’s Board.                                       
 

	 	2.1	Voting. At the Effective Time and until the termination of this Agreement, each Voting Party shall vote all Voting Shares in such manner as may be necessary to elect (and maintain in office) as members of Parent’s Board the following persons:

		(a)	Up
                                            to one (1) independent director (“Sponsor Designee”) designated by the
                                            Sponsor (as defined in the Merger Agreement); and

	 	( b)	Up to four (4) person(s) (each a “Company Designee”) designated by the Company.

	 	2.2	Initial Designees. The initial Sponsor Designee, if any, shall be determined by the Sponsor prior to the Closing through written notice to each party hereto. The initial Company Designees, if any, shall be determined by the Company through written notice to each party hereto.

	 	2.3	Obligations; Removal of Directors; Vacancies. Each of the Voting Parties, Parent and the Company agree not to take any actions that would contravene or materially and adversely affect the provisions of this Agreement and the intention of the parties with respect to the composition of Parent’s Board as herein stated. The Sponsor and the Company, as applicable, shall have the exclusive right to (a) remove their nominee(s) from the Parent’s Board, and each party hereto shall vote such party’s Voting Shares to cause the removal of any such nominee at the request of the Sponsor or the Company, as applicable, and (b) designate or nominate a director(s) for election or appointment, as applicable, to the Parent’s Board to fill a vacancy(s) created by reason of death, removal or resignation of its nominee(s) to the Parent’s Board, and each party hereto shall vote such party’s Voting Shares in favor of nominating or causing the Parent’s Board to appoint, as applicable, a replacement director(s) designated by the Sponsor or the Company, as applicable, to fill any such vacancy(s) created pursuant to clause (i) or (ii) above to be filled by a replacement director(s) designated by the Sponsor or the Company, as palpable, as promptly as practicable after such designation (and in any event prior to the next meeting or action of the Parent’s Board or applicable committee).

3.                           Election
of the Board of the Surviving Corporation. At the Effective Time, the initial directors of the Surviving Corporation shall consist
of the same persons serving on the Company’s Board of Directors as of immediately prior to the Effective Time, other than those
directors that have resigned as contemplated by Section 9.2(k) of the Merger Agreement. Such directors shall hold office until
their successors shall have been duly elected or appointed and qualified or until their earlier death, resignation or removal in accordance
with the Surviving Corporation’s articles of incorporation and bylaws.                                       
 

4.                           Committees.
To the fullest extent permitted by applicable Law, including the rules of any applicable securities exchange, each committee of the Parent’s
Board shall include the director, if any, elected to the Parent’s Board pursuant to Section 2.1(a).                                       
 

5.                           Successors
in Interest of the Voting Parties.             

	 	5.1	The provisions of this Agreement shall be binding upon the successors in interest of any Company Voting Party with respect to any of such Company Voting Party’s Voting Shares or any voting rights therein, unless such shares are sold into the public markets. Each Company Voting Party shall not, and Parent and the Company shall not, permit the transfer of any Company Voting Party’s Voting Shares (except for sales of Voting Shares into the public markets), unless and until the person to whom such securities are to be transferred shall have executed a written agreement pursuant to which such person becomes a party to this Agreement and agrees to be bound by all the provisions hereof as if such person was a Company Voting Party hereunder. 

    2

     

    

  

		5.2	The
                                            provisions of this Agreement shall not be binding upon the successors in interest of any
                                            Parent Voting Party.

6.                           Covenants.
Parent, the Company and each Voting Party agrees to take all actions required to ensure that the rights given to each Voting Party hereunder
are effective and that each Voting Party enjoys the benefits thereof. Such actions include, without limitation, the use of best efforts
to cause the nomination of the designees, as provided herein, for election as directors of Parent and the Surviving Corporation. Neither
Parent, the Company nor any Voting Party will, by any voluntary action, avoid or seek to avoid the observance or performance of any of
the terms to be performed hereunder by Parent, the Company or any such Voting Party, as applicable, but will at all times in good faith
assist in the carrying out of all of the provisions of this Agreement and in the taking of all such actions as may be necessary or appropriate
in order to protect the rights of each Voting Party hereunder against impairment.                                  
 

7.                          Grant
of Proxy. The parties agree that this Agreement does not constitute the granting of a proxy to any party or any other person; provided,
however, that should the provisions of this Agreement be construed to constitute the granting of proxies, such proxies shall be
deemed coupled with an interest and are irrevocable for the term of this Agreement.                       
 

8.                           Specific
Performance. It is agreed and understood that monetary damages would not adequately compensate an injured party for the breach of
this Agreement by any party hereto, that this Agreement shall be specifically enforceable, and that any breach of this Agreement shall
be the proper subject of a temporary or permanent injunction or restraining order, this being in addition to any other remedy to which
it is entitled at Law or in equity, and that each party waives the posting of any bond or security in connection with any proceeding
related thereto. Further, each party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened
breach and agrees that a party’s rights would be materially and adversely affected if the obligations of the other parties under
this Agreement were not carried out in accordance with the terms and conditions hereof.                                  
 

9.                           Remedies
Cumulative. All rights, powers and remedies provided under this Agreement or otherwise available in respect hereof at law or in equity
shall be cumulative and not alternative, and the exercise or beginning of the exercise of any thereof shall not preclude the simultaneous
or later exercise of any other such right, power or remedy.                                   
 

10.                         Manner
of Voting. The voting of shares pursuant to this Agreement may be effected in person, by proxy, by written consent or in any other
manner permitted by applicable law.                                   
 

11.                         Termination.
This Agreement shall terminate upon the earlier of (a) the termination of the Merger Agreement in accordance with its terms, (b) the
date that is two (2) years from the Closing Date, or (c) immediately prior to a transaction pursuant to which a person or group other
than current shareholders of Parent, Company or the Voting Parties, or their respective affiliates, will control greater than fifty percent
(50%) of Parent or Surviving Corporation’s voting power with respect to the election of directors of Parent or the Surviving Corporation.
Nothing in this Section 11 shall relieve or otherwise limit the liability of any party for breach of this Agreement prior to termination
hereof.                                  
 

12.                         Amendments
and Waivers. Except as otherwise provided herein, any provision of this Agreement may be amended or the observance thereof may be
waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of (a)
Parent, (b) the Company and (c) the holders of a majority of Voting Shares then held by the Voting Parties, voting separately as a class;
provided, however, that the right of the Company to nominate the Company Designee shall not be amended without the written consent
of a majority in interest of the stockholders of the Company; and provided further, that the right of the Shareholders’
Representative to nominate the Stockholder Designees shall not be amended without the written consent of the Shareholders’ Representative.                

    3

     

    

 

13.                         Stock
Splits, Stock Dividends, etc. In the event of any stock split, stock dividend, recapitalization, reorganization or the like, any
securities issued with respect to Voting Shares held by Voting Parties shall become Voting Shares for purposes of this Agreement.                                   
 

14.                         Notices.
Any notice or communication required or permitted hereunder shall be in writing and either delivered personally, emailed or sent by overnight
mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, and shall be deemed to be given and
received (a) when so delivered personally, (b) when sent, with no mail undeliverable or other rejection notice, if sent by email,
or (c) three (3) Business Days after the date of mailing to the address below or to such other address or addresses as such person may
hereafter designate by notice given hereunder:                
 

	 	(a)	If to the Company (or, following the Closing, the Surviving Corporation or Parent), to:

Varian
Biopharmaceuticals, Inc.

4851
Tamiami Trail North, Suite 200

Naples,
FL 34103

Attn:
Jeff Davis

E-mail:
jdavis@varianbio.com

 

with
a copy (which shall not constitute notice) to:

 

Dorsey
& Whitney LLP

111
South Main Street

Suite
2100

Salt
Lake City, UT

Attn:
Anthony W. Epps

E-mail:
epps.anthony@dorsey.com

 

		(b)	If
                                            to Parent (prior to the Closing): 

SPK
Acquisition Corp.

Xuhuiqu
Wulumuqizhonglu 99 Nong

Building
1 #502

Shanghai
China, 200031

Attn:
Sophie Ye Tao

E-mail:
sophie@spkacq.com

 

with
a copy (which shall not constitute notice) to:

 

Loeb
& Loeb LLP

345
Park Avenue

New
York, NY 10154

Attn:
Mitchell S. Nussbaum

Fax:
212-504-3013

E-mail:
mnussbaum@loeb.com

 

    4

     

    

  

		(c)	If
                                            to any Voting Party, to such address or addresses set forth below each Voting Party’s
                                            signature.

15.                         Severability.
In the event that any provision of the Agreement shall be invalid, illegal or unenforceable, the remainder of this Agreement will continue
in full force and effect and the application of such provision to other Persons or circumstances will be interpreted so as reasonably
to effect the intent of the parties hereto. The parties further agree to replace such void or unenforceable provision of this Agreement
with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such void
or unenforceable provision.                                  
 

16.                         Governing
Law. This Agreement and the legal relations between the parties arising hereunder shall be governed by and interpreted in accordance
with the laws of the State of Delaware without reference to its conflicts of laws provisions.                                  
 

17.                         Counterparts;
Electronic Execution or Delivery. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an
original and all of which together shall constitute one instrument. This Agreement may be executed electronically; any executed counterpart
of this Agreement may be delivered by facsimile or electronic mail; and any such electronically executed or delivered copy of a counterpart
signature page shall have the same force and effect as an originally executed copy hereof.                               
 

18.                         Successors
and Assigns. Except as otherwise expressly provided in this Agreement, the provisions hereof shall inure to the benefit of, and be binding
upon, the successors and assigns of the parties hereto; provided, however, that no Voting Party may assign, delegate or
otherwise transfer any of its rights or obligations under this Agreement without the consent of the Company and Parent.                                   
 

19.                         Entire
Agreement. This Agreement (together with the Merger Agreement and the other agreements and documents expressly contemplated hereby
and thereby) constitutes the full and entire understanding and agreement among the parties, and supersedes any prior agreement or understanding
among the parties, with regard to the subjects hereof and thereof, and no party shall be liable or bound to any other party in any manner
by any warranties, representations or covenants except as specifically set forth herein or therein.                       
 

[Remainder
of page intentionally left blank; signature pages follow]

    5

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

 

	 	COMPANY:
	 	 
	 	VARIAN BIOPHARMACEUTICALS, INC.
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 
	 	PARENT:
	 	 
	 	SPK ACQUISITION CORP.
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

[Signature Page to Voting Agreement]

 

    

     

    

  

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

	 	WIDER
	 	 

	 	Todd Wider
	 	 
	 	Address for Notice:
	 	 

	 	 

	 	Attention:
	 	Email:

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

 

	 	MANN
		 
	 	Paul E. Mann
	 	 
	 	Address for Notice:
	 	
	 	
	 	Attention:
	 	Email:

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

	 	DAVIS
	 	   
	 	Jeffrey B. Davis
	 	 
	 	Address for Notice:
	 	  
 
	 	Attention:
	 	Email:
	 	 

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

 

	 	LEWIS
	 	 

	 	Jonathan Lewis
	 	 
	 	Address for Notice:
	 	 
	 	

	 	Attention:
	 	Email:
	 	 

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

 

	 	KEYSTONE:
	 	 
	 	Keystone Capital Partners, LLC
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 
	 	Address for Notice:
	 	 
	 	 
	 	 
	 	Attention:	 
	 	Email:	 

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

 

	 	SPONSOR
	 	 
	 	SPK Acquisition LLC
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 
	 	Address for Notice:
	 	 
	 	 
	 	Attention:	 
	 	Email:	 

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

	 	J. CHANG
	 	 
	 	 
	 	Justin Chang
	 	 
	 	Address for Notice:
	 	 
	 	 
	 	 
	 	Attention:
	 	Email:

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

 

	 	CHOU
	 	
	 	Bryant Chou
	 	 
	 	Address for Notice:
	 	 
	 	 
	 	Attention:
	 	Email:

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

 

	 	G. CHANG
	 	 
	 	Greg Chang
	 	 
	 	Address for Notice:
	 	 
	 	 
	 	 
	 	Attention:
	 	Email:

 

[Signature Page to Voting Agreement]

 

    

     

    

 

In
Witness Whereof, the parties have caused this Agreement
to be executed as of the date first above written.

 

	 	WANG
	 	 
	 	Chris Wenbing Wang
	 	 
	 	Address for Notice:
	 	 
	 	 
	 	Attention:
	 	Email:

 

[Signature Page to Voting Agreement]CONFIDENTIAL

  

DATED 5TH JULY, 2019

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, 

MARKED BY [***], HAS BEEN
OMITTED BECAUSE IT IS BOTH (I) NOT

MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS

PRIVATE OR CONFIDENTIAL.

 

(1) CANCER RESEARCH TECHNOLOGY LIMITED

 

AND

 

(2) VARIAN BIOPHARMA LLC

 ______________________________

Licence

______________________________

 

 

    

     

    

 

CONFIDENTIAL

 

TABLE OF CONTENTS

 

	1.   INTERPRETATION	1
	2.   LICENCE	8
	3.   PERFORMANCE	10
	4.   CONSIDERATION	11
	5.   PAYMENT
    AND STATEMENT	13
	6.   ACCOUNTS	15
	7.   INTELLECTUAL
    PROPERTY MANAGEMENT	15
	8.   WARRANTY	17
	9.   INDEMNITY	18
	10.   INSURANCE	19
	11.   LIMITATION
    OF LIABILITY	19
	12.   CONFIDENTIALITY	20
	13.   TERM
    AND TERMINATION	21
	14.   EFFECTS
    OF TERMINATION	22
	15.   FORCE
    MAJEURE	24
	16.   ASSIGNMENT
    AND SUB-CONTRACTING	24
	17.   NOTICES	25
	18.   VARIATION	25
	19.   ENTIRE
    AGREEMENT	25
	20.   FURTHER
    ASSURANCE	25
	21.   WAIVER	26
	22.   SEVERABILITY	26
	23.   EXECUTION	26
	24.   ANNOUNCEMENTS
    AND USE OF NAMES	26
	25.   DISPUTE
    RESOLUTION AND GOVERNING LAW	26
	26.   CONTRACTS
    (RIGHTS OF THIRD PARTIES) ACT 1999	27

 

    i

     

    

 

CONFIDENTIAL

 

THIS AGREEMENT is made 5th July.2019.

 

BETWEEN:

 

	 	(1)	CANCER RESEARCH TECHNOLOGY
LIMITED, a company registered in England and Wales under number 1626049 with registered office at Angel Building, 407 St John
Street, London, EC1V 4AD, England (“CRT”); and

 

	 	(2)	Varian Biopharma LLC,
a company incorporated under the laws of Delaware with a principal place of business at 266 West End Avenue, New York, New York 10023,
USA (the “Licencee”).

 

WHEREAS:

 

	 	(A)	CRT is an oncology focused
technology transfer and development company, which is wholly owned by the Charity (as defined below) and is responsible for the management
and exploitation of the results derived from research funded by the Charity.

 

	 	(B)	The Licencee is a development
stage biopharma company focused on novel oncology and immunology treatments for devastating unmet medical needs.

 

	 	(C)	CRT has conducted a programme
of drug discovery research in relation to the atypical Protein Kinase C (“aPKC”) family of kinases and owns the associated
intellectual property.

 

	 	(D)	The Licencee and CRT have agreed
to enter into a licence for the aPKC intellectual property on the following terms and conditions.

 

NOW IT IS HEREBY AGREED as follows:

 

	 	1.	INTERPRETATION

 

	 	1.1	In this Agreement except where
the context requires otherwise, the following words and expressions shall have the following meanings:

 

“Affiliate” means any
person Controlling, Controlled by or under common Control with another entity.

 

“Affordable” means in
relation to a Licenced Product: (i) a determination by the UK Pricing Authority that such Licenced Product should be used within
the NHS; and/or (ii) approval by the UK Pricing Authority of the price proposed by the Licencee or its Sub-Licencee in relation to
sales of that Licenced Product in the United Kingdom (or one or more constituent countries thereof).

 

“Agreement” means this
agreement and each of the Schedules as amended from time to time in accordance with Clause 18.

 

“Annual Fee Preclinical”
means the non-refundable sum of [***].

 

“Annual Fee NDA” means
the non-refundable sum of [***].

 

“Arising Intellectual Property”
means all Materials and Know How (other than that comprising Licenced Intellectual Property) conceived or generated after the Effective
Date by or on behalf of the Licencee or its Sub-Licencees in the course of exercising the licence rights granted under Clause 2.1;
and any Patent Rights which claim any such Materials and/or inventions described or comprised in such Know How.

 

“Arising Patents” means
a Patent application claiming Arising Intellectual Property or any use thereof.

 

    1

     

    

 

CONFIDENTIAL

 

“Business Day” means a
day other than a Saturday, Sunday or any public holiday in England or any public holiday in the United States of America recognised by
Federal law.

 

“Change of Control” means,
with respect to a Party, (i) a merger or consolidation of such Party with a Third Party that results in the voting securities of
such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged,
ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving
entity immediately after such merger or consolidation, (ii) a transaction or series of related transactions in which a Third Party,
together with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding
securities of such Party. or (iii) the sale or other transfer to a Third Party of all or substantially all of such Party’s
assets or all or substantially all of such Party’s assets.

 

“Charity” means Cancer
Research UK, a company limited by guarantee (registered in England and Wales under number 4325234) and a charity (registered in England
under number 1089464 and registered in Scotland under number 5C041666) of Angel Building, 407 St John Street, London, EC1V 4AD, United
Kingdom.

 

“Combination Product”
means any product that is sold by the or on behalf of the Licencee in a finished dosage form, or in a single package, containing the Licenced
Product in combination with, or co-packaged with, one or more other active pharmaceutical ingredients.

 

“Commencement” means,
in relation to a clinical trial, the date upon which administration of a Licenced Product to the first human subject has occurred, whether
such subject is a healthy volunteer or a patient.

 

“Commercially Reasonable Efforts”
means the efforts and resources commonly used by a company of a similar size and with similar resources to the Licencee (or, where applicable,
its Sub-Licencee) for a product at a similar stage in its life cycle, taking into consideration its safety, efficacy, patent or other
proprietary position, and all other relevant factors.

 

“Competent Authority”
means any local or national agency, court, authority, department, inspectorate, minister, ministry official or public or statutory person
(whether autonomous or not) of, or of any government of, any country having jurisdiction over the Agreement or either of the Parties or
over the development or marketing of medicinal products such as the FDA or the European Medicines Agency.

 

“Confidential Information”
means any information, in tangible or non-tangible form (including oral disclosure) including Know How, research and development plans,
information relating to the customers, suppliers, business partners, clients, finances, business plans and products (in each case actual
or prospective) of a Party, the terms of this Agreement, and any other technical or business information (whether or not marked as confidential),
which is obtained by either Party from the other (or its representatives) pursuant to this Agreement. Licenced Know How shall be deemed
the Confidential Information of each Party and each Party shall be deemed the “Receiving Party” with respect thereto.

 

“Control” means the possession
(directly or indirectly) of fifty per cent (50%) or more of the voting stock or other equity interest of a subject entity with the
power to vote, or the power in fact to control the management decisions of such entity through the ownership of securities or by contract
or otherwise and “Controlling” and “Controlled by” shall be construed accordingly.

 

“CRT Reviewers” means
any research institution(s) involved in the generation or development of the Licenced Intellectual Property, and that CRT is obliged to
report to on the revenues received of Licenced Products and the revenues received by CRT pursuant to Clause 4; and as contemplated
by Clause 16.2, any actual or potential royalty purchaser.

 

    2

     

    

 

CONFIDENTIAL

 

“Development Plan” for
the first [***] from the Effective Date shall mean the initial Development Plan annexed at Schedule 5. Thereafter, the Development
Plan means a plan updated by the Licencee in accordance with Clause 3.4.4 which describes: (i) the Key Activities; (ii) the
relevant timescales within which such Key Activities are anticipated to be taken; (ii) additional operational details including an
overview of the information contained in regulatory filings such as Pre-IND, IND; and (iv) the Annual Reports. Such plan will reflect
industry practice and describe the development of Licenced Products across a range of Oncology Indications. For the avoidance of doubt,
the initial Development Plan annexed at Schedule 5 shall satisfy the requirements of this definition for the initial [***] only and
not thereafter.

 

“Effective Date” means
the date this Agreement is made.

 

“Enterprise Value” means
the total value of the financial instruments representing ownership interests (equity) in a business entity plus the value of its debt
or debt-related liabilities, minus any cash or cash equivalents available to meet those liabilities. All amounts will be calculated based
on US GAAP (Generally Accepted Accounting Principles).

 

“Exclusive Arising Intellectual
Property” has the meaning given in Clause 14.1.7(a).

 

“Executive Officers” means
Chief Executive Officer of the Licencee, and the Chief Executive Officer of CRT or such other authorised officer of a Party as may be
substituted from time to time upon the giving of written notice to the other Party.

 

“Existing Evaluating Company”
means the company that currently has an agreement dated [***] with CRT to undertake an evaluation of the Licenced Materials.

 

“Expenses” means all reasonable
and customary costs and expenses incurred from time to time by or on behalf of CRT in protecting any Licenced Intellectual Property or
Arising Intellectual Property, including without limitation:

 

	 	i.	all Patent Costs;

 

	 	ii.	travel and other out-of-pocket
expenditure;

 

	 	iii.	courier charges and third party
printing costs; and

 

	 	iv.	any non-recoverable taxes or
charges including Value Added Tax which may be imposed.

 

“Expert”
means a suitably qualified independent expert appointed by agreement between the Parties. However, in the event that the Parties are
unable to reach agreement within thirty (30) Business Days of either Party seeking in writing to the other to appoint such expert,
each Party shall submit two (2) names to the President for the time being of the Association of the British Pharmaceutical Industry
(or any successor body thereto), who shall select an individual from the names submitted.

 

“Extended
Exclusivity Period” means any period during which one of the following subsists in respect of a Licenced Product: Orphan Drug
Designation, paediatric designation, clinical trial data exclusivity or other exclusivity (excluding a Patent) granted by a Competent
Authority beyond the expiry of the relevant Patent.

 

“FDA”
means the United States Food and Drug Administration or any successor to it.

 

“Field”
means the diagnosis, prevention or treatment of human disease.

 

“First
Commercial Sale” means, with respect to a Licenced Product, the first transfer or disposition for value of such Licenced Product
to a Third Party, after all relevant Regulatory Authorisations for the transfer or disposition of such Licenced Product have been obtained
in respect of the relevant region or country.

 

    3

     

    

 

CONFIDENTIAL

 

“Force
Majeure” means in relation to either Party any event or circumstance which is beyond the reasonable control of that Party and
results in or causes the failure of that Party to perform any or all of its obligations under this Agreement including act of God, lightning,
fire, storm, flood, earthquake, strike, lockout or other industrial disturbance, war, terrorist act, blockade, revolution, riot, insurrection,
civil commotion, public demonstration, sabotage, act of vandalism, explosion, provided that lack of funds shall not be interpreted as
a cause beyond the reasonable control of that Party.

 

“IND”
means an investigational new drug application filed with the FDA, or the equivalent application or filing filed with any equivalent Competent
Authority outside the United States of America (including any supranational agency such as the European Medicines Agency) necessary to
commence human clinical trials in such jurisdiction.

 

“Indemnified
Parties” means CRT, the Charity, any academic institutions whose intellectual property and/or Know How has been comprised in
the Licenced Intellectual Property and their respective officers, employees and agents.

 

“Indication”
means a disease classification as defined within the ‘International Statistical Classification of Diseases and Related Health Problems’
as published from time to time by the World Health Organization (e.g. “C50 Malignant neoplasm of Breast”, “C92 Myeloid
leukaemia”, “B20 Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases” and “M34
Systemic sclerosis”).

 

“Intellectual
Property” means Materials, Patents and Know How.

 

“IP
Strategy” means the filing, prosecution and/or maintenance of the Patents.

 

“Key
Activity” means any of the following in relation to a Licenced Product:

 

	 	i.	significant research activity
related to biological processes that a Licenced Product would or could affect, including, but not limited to, animal studies;

 

	 	ii.	active preclinical work required
for any contemplated clinical trial, including any toxicology or pharmacokinetic work;

 

	 	iii.	active planning, for up to
a maximum of [***] (or such longer period as may be agreed upon by CRT and the Licencee, such agreement not to be unreasonably withheld)
of a clinical trial (or in the event of issues arising with a Competent Authority in relation to a clinical trial, active negotiation
with such Competent Authority and/or replanning of the clinical trial);

 

	 	iv.	actively seeking to obtain
the necessary IND or other approvals to carry out a clinical trial;

 

	 	v.	active enrolment of patients
into, or participation of patients in, a clinical trial, where relevant in accordance with the protocol in order to determine if the
primary end point has been met;

 

	 	vi.	active monitoring, analysis
or reporting on the data arising from a clinical trial where relevant in accordance with the protocol in order to determine if the primary
end point has been met;

 

    4

     

    

 

CONFIDENTIAL

 

	 	vii.	manufacture or formulation
of a Licenced Product for use in a clinical trial, including active process development work in support of planned manufacture; and

 

	 	viii.	preparation for and making
submissions to regulatory agencies for an NDA or awaiting the outcome of such submission.

 

“Know
How” means technical and other information, including, ideas, concepts, inventions, discoveries, data, formulae, algorithms,
specifications, clinical data, information relating to Materials (including biological and chemical structures and functions as well
as methods for synthesising chemical compounds), procedures for experiments and tests, results of experimentation and testing, results
of research and development including laboratory records and data analyses. Information in a compilation or a compilation of information
may be Know How notwithstanding that some or all of its individual elements are in the public domain.

 

“Licenced
Intellectual Property” means the Licenced Know How, Licenced Patents and Licenced Materials.

 

“Licenced
Know How” means the Know How described in Schedule 2.

 

“Licenced
Materials” means the Materials described in Schedule 3.

 

“Licenced
Patents” means: (i) the Patents detailed in Schedule 1; (ii) any Patents filed by the Licencee on or after the
Effective Date claiming any part of the Licenced Materials and/or any inventions described or comprised within the Licenced Know How;
and (iii) any Patents claiming priority from the Patents described in (i) and (ii).

 

“Licenced
Product” means any product: (i) which falls within the scope of one or more Valid Claims of any of the Licenced Patents
in the relevant country or territory; and/or (ii) developed using or incorporating any part of the Licenced Intellectual Property,
including any metabolites, prodrugs, salts, hydrates, solvates, esters, intermediates, polymorphs, isomers, analogues and derivatives,
which are developed by or on behalf of the Licencee or its Sub-Licencees.

 

“Major
Markets” means [***].

 

“Materials”
means any chemical or biological materials including any: organic or inorganic element or compound; nucleotide or nucleotide sequence
including DNA and RNA sequences; gene; vector or construct including plasmids, phages, bacterial vectors, bacteriophages and viruses;
host organism including bacteria, fungi, algae, protozoa and hybridomas; eukaryotic or prokaryotic cell line or expression system or
any development strain or product of that cell line or expression systems; protein including any peptide or amino acid sequence, enzyme,
antibody or protein conferring targeting properties and any fragment of a protein or a peptide enzyme or antibody; drug or pro-drug;
assay or reagent; any other genetic or biological material or micro-organism or any transgenic animal; and any physical property rights
relating to any of the foregoing.

 

“Milestone
Events” has the meaning given in Clause 4.2.

 

“Milestone
Payments” has the meaning given in Clause 4.2.

 

    5

     

    

 

CONFIDENTIAL

 

“NDA”
means an application for approval to market a product commercially such as the New Drug Application filed pursuant to the requirements
of the FDA, as more fully defined in 21 CFR.§ 314.3 et seq, or a Biologics Licence Application filed pursuant to the requirements
of the FDA, as more fully defined in 21 CFR § 601, or a Marketing Authorisation application filed pursuant to the requirements
of European Directive 2001/ 83/ EC, or any equivalent or similar application filed with any other Competent Authority in any country
or region in the Territory, together, in each case, with all additions, deletions or supplements thereto.

 

“Net
Revenue” means the aggregate sums received by CRT in respect of any commercial exploitation of a Licenced Product, after the
deduction of all Expenses.

 

“Net
Sales” means the gross amount invoiced on account of sales of Licenced Product by the Licencee or any of its Affiliates or
Sub-Licencees in the Territory (but not including sales between the Licencee, its Affiliates or Sub-Licencees where the Licenced Product
is intended for resale) less the following deductions directly relating to such sales of Licenced Product:

 

[***]

 

The Net Sales
of a Combination Product, for the purposes of determining royalty payments, shall be determined by [***].

 

For purposes
of this definition, the Licenced Product shall be considered “sold” and “deductions” allowed when recorded as
invoiced in the Licencee’s, its Affiliate’s or Sub-Licencee’s financial statements prepared in accordance with the
relevant accounting standards.

 

“NHS”
means the National Health Service in England and Wales (or any successor organisation thereto).

 

“Non-Topical
Licenced Product” means any Licenced Product which is not a Topical Licenced Product.

 

“Oncology
Indication” means an Indication in the range COO – D48 (e.g. “C50 Malignant neoplasm of Breast”, “C92
Myeloid leukaemia”).

 

“Orphan
Drug Designation” means designation as an orphan drug or equivalent under relevant national or other applicable regulations
and/or legislation in any part of the world, including under the US Orphan Drug Act of 1983 or Orphan Drug Regulation 141/2000 in the
European Union.

 

“Parties”
means CRT and the Licencee and “Party” shall mean any of them.

 

“Patent
Costs” means any costs and expenses incurred in filing, prosecuting, maintaining, defending and enforcing the Patents, including
official filing, prosecution, maintenance and renewal fees, patent attorney, translation, legal and other professional fees and expenses
and costs and expenses associated with any opposition or interference action.

 

“Patents”
means any patent applications, patents, author certificates, inventor certificates, utility models, and all foreign counterparts of them
and includes all priority applications, divisionals, renewals, continuations, continuations-in-part, extensions, reissues, substitutions,
confirmations, registrations, revalidations, re-examinations and additions of or to them, as well as any Supplementary Protection Certificate,
or any like form of protection.

 

“Phase
I Trial” means a clinical trial in which a Licenced Product is administered to human subjects at multiple dose levels with
the primary purpose of determining safety, metabolism, and pharmacokinetic and pharmacodynamic properties of the Licenced Product, and
consistent with 21 CFR § 312.21(a) and any microdosing clinical trial conducted pursuant to the FDA’s 2006 Guidance on
Exploratory Investigational New Drugs or any equivalent arrangements.

 

“Phase II
Trial” means a clinical trial of a Licenced Product in human patients, the principal purposes of which are to make a preliminary
determination that the Licenced Product is safe for its intended use, to determine its optimal dose, and to obtain sufficient information
about the Licenced Product’s efficacy to permit the design of Phase Ill Trials, and consistent with 21 CFR 312.21(b).

 

    6

     

    

 

CONFIDENTIAL

 

“Phase III
Trial” means a human clinical trial of a Licenced Product, which trial is designed: (a) to establish that the Licenced
Product is safe and efficacious for its intended use; (b) to define warnings, precautions and adverse reactions that are associated
with the Licenced Product in the dosage range to be prescribed; and (c) consistent with 21 CFR § 312.21(c). Any Phase II
Trial that is adapted to be a larger scale trial and to function as a pivotal trial for the purpose of obtaining Regulatory Authorisation
of a Licenced Product, shall be deemed a Phase III Trial.

 

“Price
Approval” means, in those countries in the Territory where a Competent Authority may approve or determine pricing and/or pricing
reimbursement for pharmaceutical products, such approval or determination.

 

“Progress
Report” means a written report produced by the Licencee in respect of: (i) the progress of development of Licenced Products
against the current Development Plan; (ii) the progress of any applications for Regulatory Authorisation and (where relevant) Price
Approvals; and (iii) the progress of and plans for marketing and sale of Licenced Products.

 

“Quarter”
means any of the three-monthly periods commencing on the first day of any of the months of January, April, July, and October in any year
and “Quarterly” has a corresponding meaning.

 

“Regulatory
Authorisations” means all authorisations, approvals, clearances, and licences of a Competent Authority (including an NDA) that
may be required in any country of the Territory prior to commercial sale of the relevant Licenced Product in the Field, including any
necessary variations thereto, but excluding any Price Approvals.

 

“Sub-Licencee”
means a person to whom a sub-licence is granted in accordance with Clause 2.4 in respect of the whole or any part of the rights
granted under this Agreement.

 

“Sub-Licence
Revenue” means [***].

 

“Supplementary
Protection Certificate” means a right based on a patent pursuant to which the holder of the right is entitled to exclude third
parties from using, making, having made, selling or otherwise disposing or offering to dispose of, importing or keeping the product to
which the right relates, such as supplementary protection certificates in Europe, and any similar right anywhere in the world.

 

“Term”
means the term of this Agreement determined in accordance with Clause 13.1.

 

“Territory”
means worldwide.

 

“Third
Party” means a person other than a Party.

 

“Third
Party Service Provider” means a Third Party who provides research, development, consultancy and/or manufacturing services to
the Licencee or its Affiliate or Sub-Licencee in connection with Licenced Products, including contract research organisations, universities
and hospitals. However, a Tobacco Party may not act as a Third Party Service Provider.

 

“Tobacco
Party” means any person: (i) who develops; sells or manufactures tobacco products; and/ or (ii) which makes the majority
of its profits from the importation, marketing, sale or disposal of tobacco products. Furthermore, Tobacco Party shall include any person
that is Controlled by or under common Control with any such person.

 

“Topical
Licenced Products” means a Licenced Product comprising a pharmaceutical composition administered to the surface of the skin
of a subject.

 

    7

     

    

 

CONFIDENTIAL

 

“UK
Pricing Authority”, means any supra-national, national or regional government department, authority, agency or entity (including
a non-departmental public body or similar entity) with responsibility for evaluating the cost effectiveness of medicinal products in
the United Kingdom (or one or more constituent countries thereof) or otherwise determining whether the NHS (or constituent parts thereof)
should purchase medicinal products.

 

“Valid
Claim” means a claim of any Patent which has not expired, been withdrawn, abandoned or surrendered or been refused, revoked
or held invalid in an unappealed or unappealable final decision rendered by a court or other governmental agency of competent jurisdiction
in the relevant country or territory.

 

“Year”
means a calendar year.

 

	 	1.2	In this Agreement:

 

	 	1.2.1	unless the context requires
otherwise, all references to a particular Clause, paragraph or Schedule shall be references to that clause, paragraph or schedule, in
or to this Agreement;

 

	 	1.2.2	the table of contents and headings
are inserted for convenience only and shall be ignored in construing this Agreement;

 

	 	1.2.3	unless the contrary intention
appears, words importing the masculine gender shall include the feminine and vice versa and words in the singular include the plural
and vice versa;

 

	 	1.2.4	unless the contrary intention
appears, words denoting persons shall include any individual, partnership, company, corporation, joint venture, trust association, organisation
or other entity, in each case whether or not having separate legal personality;

 

	 	1.2.5	references to the words “include”
or “including” shall be construed without limitation to the generality of the preceding words.

 

	 	2.	LICENCE

 

	 	2.1	Subject to the provisions of
this Agreement, CRT hereby grants the Licencee an exclusive licence under the Licenced Intellectual Property to research, develop, use,
keep, make, have made, import, sell and otherwise exploit Licenced Products, including Topical Licenced Products and Non-Topical Licenced
Products, in the Field in the Territory.

 

	 	2.2	The Licencee shall not do or
procure or purport to authorise the doing of any act within the scope of the Licenced Intellectual Property other than as permitted in
this Agreement. No licence to use any Intellectual Property is granted or implied to either Party except the rights expressly granted
in this Agreement.

 

	 	2.3	The Licencee hereby grants
CRT (a) a non-exclusive, fully paid up, sub-licensable, worldwide, licence to use the Licenced Intellectual Property and knowhow
to enable CRT to grant the rights necessary for the Existing Evaluating Company to evaluate the Licenced Materials to the extent necessary
for such Existing Evaluating Company to complete its evaluation of the Licenced Materials and; (b) a non-exclusive, fully paid up,
sub-licensable, worldwide, perpetual, irrevocable, licence to use the Licenced Intellectual Property for non-commercial academic research
use. If CRT becomes aware of any Patents related to the Licenced Products arising from such evaluation or non-commercial academic research
use rights granted under this clause 2.3 (“New IP”), CRT shall use reasonable efforts to make the Licencee aware
of such New IP and to the extent CRT controls such New IP and the New IP is unencumbered, CRT shall, if requested by the Licencee in
writing, enter into good faith negotiations with the Licencee to grant a Licence to such New IP on terms to be agreed and consistent
with pharmaceutical industry standards.

 

    8

     

    

 

CONFIDENTIAL

 

	 	2.4	The Licencee shall be entitled
to grant sub-licences (through multiple tiers) in respect of the rights granted under this Agreement, provided that with respect to any
sub-licence granted to an entity:

 

	 	2.4.1	prior to grant it informs CRT
in writing of the terms of any sub-licence proposed to be entered into and the identity of the proposed Sub-Licencee. The Licencee undertakes
to contractually oblige any Sub-Licencee to whom it sub-licences any such Licenced Products and/or the Licenced Intellectual Property
to give an undertaking which substantially replicates the one set out in this Clause 2.4.1 i.e. prior to grant it informs CRT in
writing of the terms of any sub-licence proposed to be entered into and the identity of the proposed Sub-Licencee;

 

	 	2.4.2	any sub-licence granted by
the Licencee shall be expressed to terminate automatically on the termination of this Agreement for any reason. In the event this Agreement
is terminated for any reason, including but not limited to breach or insolvency, CRT will negotiate with any such sub-Licence holder
to obtain a direct licence under CRT’s rights in the Licenced Products and/or the Licenced Intellectual Property to the extent
such terms and conditions arise from or apply to the grant of rights and Licences from the Licencee to sub-Licencee under the any sub-Licence
agreement, including all payment and termination provisions of the CRT Agreement (the “Stand-By Licence”). The Stand-By
Licence will be concluded under similar terms and conditions as the ones granted initially to the Licencee under this Agreement, except
for the provisions otherwise to be negotiated or agreed in principal in good faith with any such sub-Licencee; provided, that CRT will
grant such rights and Licences only after this Agreement first terminates or otherwise ceases to be in effect for any reason, whether
or not in connection with any laws governing an insolvency, reorganization, bankruptcy, liquidation or winding up of the Licencee as
applicable. Nothing in this clause 2.4.2 shall affect, modify or diminish in any way, any of CRT’s rights or remedies relating
to breaches of this Agreement by the Licencee.

 

	 	2.4.3	the Licencee shall ensure that
there are included in the terms of any sub-licence substantially equivalent obligations and undertakings on the part of the Sub-Licencee
to those applying to the Licencee in this Agreement (except this Clause 2.4.3 including Clause 3 (performance), Clause 7.11
(patent enforcement), Clause 9.1 (indemnity), Clause 12 (confidentiality) and Clause 14.1.7 (CRT’s rights on termination)
and shall further ensure that all Sub-Licencees duly comply with the same;

 

	 	2.4.4	within [***] of the grant of
any sub-licence by the Licencee, the Licencee shall provide CRT with a copy of such sub-licence at the Licencee’s expense, which
copy may be redacted of information that is reasonably not related to the Licencee’s obligations hereunder; and

 

	 	2.4.5	no sub-licence shall be granted
to a Tobacco Party; and

 

	 	2.4.6	the sub-licence shall be entered
into on an arms-length basis reflecting the market value of the rights granted.

 

The foregoing
obligations shall not apply in relation to contracts the Licencee enters into with Third Party Service Providers, provided that: (a) such
contracts relate to the provision of services to the Licencee or a Sub-Licencee in connection with the Licenced Products; and (b) no
rights are granted to the Third Party Service Provider to: (i) research, develop or manufacture its own products; or (ii) sell
the Licencee’s Products.

 

	 	2.5	Any breach of Clause 2.4 shall be deemed to be a material breach.

 

	 	2.6	The grant of any sub-licence shall be without prejudice to the Licencee’s obligations under this Agreement. Any act or omission of any Sub-Licencee which, if it were the act or omission of the Licencee would be a breach of any of the provisions of this Agreement, will be deemed to be a breach of this Agreement by the Licencee who will be liable to CRT accordingly.

 

    9

     

    

 

CONFIDENTIAL

 

	 	3.	PERFORMANCE

 

	 	3.1	The Licencee will use Commercially
Reasonable Efforts to:

 

	 	3.1.1	develop one or more Topical
Licenced Products and one or more Non-Topical Licenced Products suitable for use in human clinical trials according to the Development
Plan. Successful fundraising and initiation of development of a Non-Topical Licenced Product in line with the current Development Plan
within [***] from the Effective Date will be considered a Commercially Reasonable Effort towards the development of a Non-Topical Licenced
Product for the initial [***] period from the Effective Date.

 

	 	3.1.2	pursue Regulatory Authorisation
and (where applicable) Price Approvals in each of the Major Markets for those Licenced Products in clinical development;

 

	 	3.1.3	subject to receipt of applicable
Regulatory Authorizations and (where applicable) Price Approvals, introduce and commercialise each Licenced Product; and

 

	 	3.1.4	without prejudice to the generality
of the foregoing, develop and commercialise tat least one Topical Licenced Product and one Non-Topical Licenced Product with an application
in an Oncology Indication.

 

	 	3.2	The Licencee will use Commercially
Reasonable Efforts to make each Licenced Product available throughout [***] within [***] of launching such Licenced Product in any other
country in the Territory, and subject to receipt of Regulatory Authorisation and Price Approval in the United Kingdom.

 

	 	3.3	In the event that a Licenced
Product is launched or ready to be launched in the United Kingdom, the Licencee will use Commercially Reasonable Efforts to ensure that
such Licenced Product is made available throughout the United Kingdom at an Affordable Price.

 

	 	3.4	The Licencee shall:

 

	 	3.4.1	provide CRT with a Progress
Report at least once every [***] for the first [***] following the Effective Date and [***] after the date upon which administration
of a Licenced Product to the first human subject has occurred;

 

	 	3.4.2	promptly respond to any reasonable
queries that CRT may have from time to time following receipt of a Progress Report;

 

	 	3.4.3	at CRT’s reasonable request,
meet from time to time with CRT (either in person or by teleconference if a face-to-face meeting is not practical) to discuss the content
of a particular Progress Report; and

 

		3.4.4	update
                                            the Development Plan and provide a copy of the same to CRT at least once every [***] for
                                            the first [***] following the Effective Date and [***] thereafter.

 

	 	3.5	The Licencee shall use Commercially
Reasonable Efforts to seek to raise investment during the Term. The Licencee will use Commercially Reasonable Effort to raise monies
from investors as described in Schedule 6 to discharge its obligations under this Agreement (including pursuant to Clause 3 and
Clause 4). The Licencee will keep CRT reasonably apprised of progress with such fundraising activities. Further, the Licencee shall
assure that all regulations, rules and laws governing such fundraising are complied with and that such funds will only be used in the
furtherance of the Licensee’s corporate purpose and business plan.

 

    10

     

    

 

CONFIDENTIAL

 

	 	3.6	If at any time during the course
of the development or commercialisation of a Topical Licenced Product or a Non-Topical Licenced Product, the Licencee fails to meet one
or more of its obligations under Clauses 3.1 to 3.5 inclusive in relation to such Topical Licenced Product or Non-Topical Licenced
Product for a period of [***] or more, then CRT shall have the right to give written notice to the Licencee requesting detailed written
justification for such failure and the Licencee shall provide such detailed written justification to CRT within [***] of the date of
CRT’s request and shall take substantive steps to remedy such failure within [***] of the date of CRT’s request. If the Licencee
fails to provide such justification to CRT within [***] of the date of CRT’s request and/or take substantive steps to remedy such
failure within [***] of the date of CRT’s request, then, on notice by CRT to the Licencee (to be given in CRT’s sole discretion),
the relevant provisions of Clause 13 shall apply. Any dispute between the Parties as to whether a diligence failure has arisen or
whether substantive steps have been taken to remedy a diligence failure shall be resolved by the Expert.

 

		4.	CONSIDERATION

 

		4.1	For
                                            the first [***] from the Effective Date, the Licencee shall pay the Annual Fee Preclinical
                                            to CRT within [***] of each anniversary of the Effective Date. From the [***] from the Effective
                                            Date until the first submission of an NDA, the Licencee shall pay the Annual Fee NDA to CRT
                                            within [***] of the Effective Date. The Annual Fee Preclinical and the Annual Fee NDA shall
                                            not be creditable against any other payment due under this Agreement.

 

	 	4.2	The Licencee shall pay the
following payments (“Milestone Payments”) to CRT upon the first occurrence of each of the following events (“Milestone
Events”):

 

	 	4.2.1	in relation to a Topical Licenced
Product:

 

	 	(a)	Commencement of a Phase II
Trial, [***];

 

	 	(b)	Commencement of a Phase III
Trial, [***];

 

	 	(c)	acceptance of an NDA by the
FDA in the United States of America, [***];

 

	 	(d)	acceptance of an NDA by the
European Medicines Agency in the European Union, [***];

 

	 	(e)	the aggregate worldwide Net
Sales of all Topical Licenced Products exceeding [***] in a calendar year, the sum of [***];

 

	 	(f)	the aggregate worldwide Net
Sales of all Topical Licenced Products exceeding [***] in a calendar year, the sum of [***];

 

	 	4.2.2	in relation to a Non-Topical
Licenced Product:

 

	 	(a)	Commencement of a Phase II
Trial for each of the first and second Indications, [***];

 

	 	(b)	Commencement of a Phase III
Trial for each of the first and second Indications, [***];

 

	 	(c)	acceptance of an NDA by the
FDA for each of the first and second Indications in the United States of America, [***];

 

    11

     

    

 

CONFIDENTIAL

 

	 	(d)	acceptance of an NDA by the
European Medicines Agency for each of the first and second Indications in the European Union, [***];

 

		(e)	the
                                            aggregate worldwide Net Sales of all Non-Topical Licenced Products exceeding [***] in a calendar
                                            year, the sum of [***];

 

	 	(f)	the aggregate worldwide Net
Sales of all Non-Topical Licenced Products exceeding [***] in a calendar year, the sum of [***];

 

	 	(g)	the aggregate worldwide Net
Sales of all Non-Topical Licenced Products exceeding [***] in a calendar year, the sum of [***];

 

A Milestone
Event may be triggered by the actions of the Licencee, its Sub-Licencees or any person acting on behalf of the Licencee or its Sub-Licencees
(including an Affiliate of either of them). Milestone Events may be triggered by the second and any subsequent Licenced Products in respect
of an Indication, unless such Milestone Event has already been triggered by a preceding Licenced Product in that Indication. Upon the
occurrence of each Milestone Event in respect of an Indication, any Milestone Event listed before it in this Clause 4 which has
not occurred shall be deemed to have occurred in relation to that Indication; provided, that the foregoing sentence shall not apply with
respect to the Milestone Events described in Clauses 4.2.1(c), 4.2.1(d), 4.2.2(c), or 4.2.2(d), each of which Milestone Events needs
to be achieved before becoming payable. An NDA may be submitted in respect of the entire European Union (through a Competent Authority
such as the European Medicines Agency) or in respect of one or more individual countries within the European Union (through the Competent
Authorities of each such country).

 

	 	4.3	Subject to Clause 4.5,
the Licencee shall pay to CRT:

 

	 	4.3.1	[***] of Sub-Licence Revenue,
if the relevant sub-licence is granted by the Licencee prior to the Commencement of a Phase I Trial; and

 

	 	4.3.2	[***] of Sub-Licence Revenue,
if the relevant sub-licence is granted by the Licencee after Commencement of a Phase I Trial and prior to the Commencement of a
Phase III Trial; and

 

	 	4.3.3	[***] of Sub-Licence Revenue,
if the relevant Sub-Licence is granted by the Licencee on or after the Commencement of a Phase III Trial.

 

	 	4.4	Any agreement the Licencee
enters into that results in a change of Control must be on and arm’s length basis and for full market price value per US GAAP.

 

	 	4.4.1	In the event that a Third Party,
a Sub-Licencee, or an Affiliate of a Party or a Sub-Licencee acquires Control of the Licencee, CRT shall be entitled to receive forthwith
upon completion of the acquisition:

 

	 	(a)	if such change of Control completes
before the commencement of a Phase II clinical trial, the Licencee will pay a sum equivalent of [***] to CRT; or

 

	 	(b)	if such change of Control completes
after the commencement of a Phase II clinical trial and if the Enterprise Value is [***], the Licencee will pay a sum equivalent
of [***]to CRT; or

 

	 	(c)	if such change of Control completes
after the commencement of the Phase II clinical trial and if the Enterprise Value is [***], the Licencee will pay [***] to CRT.

 

	 	4.5	The Licencee shall pay royalties
to CRT on a Licenced Product by Licenced Product, and country by country basis until the later of:

 

    12

     

    

 

CONFIDENTIAL

 

	 	4.5.1	[***];

 

	 	4.5.2	[***]; and

 

	 	4.5.3	[***].

 

	 	4.6	The following royalty rates
shall apply to the respective tiers of aggregate Net Sales of all Licenced Products achieved across all Indications in a given Year:

 

	 	4.6.1	[***]; and

 

	 	4.6.2	[***].

 

Notwithstanding
the foregoing, (a) if the Licencee is required to, and obtains a licence under any Intellectual Property from any third party(ies)
in order to make, have made, use, offer to sell, sell or import Licenced Product ( “Additional Third Party Licences”), [***]
of the consideration (including upfront payments, licence fees, milestone payments and royalties) actually paid under such Additional
Third Party Licences by the Licencee in connection with the manufacture, use, sale or import, as applicable, of Licenced Product shall
be creditable against the royalty payments due CRT by the Licencee with respect to the sale of Licenced Product; and (b) if there
is no Valid Claim of a Licenced Patent claiming the composition of matter of a given Licenced Product in a given country, then the royalties
payable in connection with such Licenced Product and country shall be reduced by [***]. However, the royalty due to CRT under this clause
will not be reduced to lower than [***] if the royalty rate under Clause 4.6.1 applies or [***] if the royalty rate under Clause 4.6.2
applies. For the avoidance of doubt, if both subclauses (a) and (b) above apply, in no event shall the royalties owed by the Licencee
to CRT for a particular Licenced Product be reduced to [***] if Clause 4.6.1 applies or [***] if Clause 4.6.2 applies.

 

		4.7	In
                                            the event that any Milestone Event is triggered by a Sub-Licencee, the Licencee shall pay
                                            to CRT the greater of the Milestone Payment due under Clause 4.2 or the payment due
                                            in respect of such Milestone Event under Clause 4.3 (if any) but not both.

 

		5.	PAYMENT
                                            AND STATEMENT

 

		5.1	All
                                            payments due to CRT under this Agreement shall be made in United States Dollars (USD) in
                                            cleared funds to the following bank account:

 

[***]

 

or such other
account as CRT may notify the Licencee from time to time.

 

		5.2	The
                                            Licencee shall pay to CRT:

 

		5.2.1	the
                                            Annual Fee on the dates specified in Clause 4.1;

 

		5.2.2	the
                                            Milestone Payments within sixty (60) days of the Milestone Event occurring;

 

		5.2.3	CRT’s
                                            share of Sub-Licence Revenue due under Clause 4.3 Quarterly within sixty (60) days
                                            of the end of the Quarter in which such Sub-Licence Revenue is received by the Licencee;

 

		5.2.4	the
                                            royalties due pursuant to Clause 4.4 Quarterly within sixty (60) days of the end
                                            of each Quarter in which the relevant Net Sales is invoiced by the Licencee or a Sub-Licencee;
                                            and

 

		5.2.5	Patent
                                            Costs as specified in Clause 7.1.

 

    13

     

    

 

CONFIDENTIAL

 

		5.3	Where
                                            Licenced Products are sold or Sub-Licence Revenue is received in a currency other than United
                                            States Dollars (USD), the rate of exchange to be used for converting such other currency
                                            into United States Dollars (USD) shall be the relevant mid-spot rate quoted by the Financial
                                            Times on the last Business Day of the Quarter to which they relate.

 

		5.4	All
                                            costs of transmission and currency conversion shall be borne by the Licencee.

 

		5.5	All
                                            payments to CRT under this Agreement are expressed to be exclusive of value added tax howsoever
                                            arising, and the Licencee shall pay to CRT in addition to those payments or, if earlier,
                                            on receipt of a tax invoice or invoices from CRT, all value added tax for which CRT is liable
                                            to account in relation to any supply made or deemed to be made for value added tax purposes
                                            pursuant to this Agreement.

 

		5.6	All
                                            sums payable under this Agreement shall be paid without deduction or deferment in respect
                                            of any disputes or claims whatsoever and in respect of any taxes except any tax which the
                                            Licencee is required by law to deduct or withhold. If the Licencee is required by law to
                                            make any such tax deduction or withholding, the Licencee shall give reasonable assistance
                                            to CRT to claim exemption from or (if that is not possible) a credit for the deduction or
                                            withholding under any applicable double taxation or similar agreement from time to time in
                                            force, and shall promptly give CRT proper evidence as to the deduction or withholding and
                                            payment over of the tax deducted or withheld.

 

		5.7	Where
                                            CRT does not receive payment of any sums due to it by the due date, interest shall accrue
                                            both before and after any judgement on the sum due and owing to CRT at the rate equivalent
                                            to an annual rate of [***] over the then current base rate of Natwest Bank Plc, calculated
                                            on a daily basis, until the full amount is paid to CRT, without prejudice to CRT’s
                                            right to receive payment on the due date.

 

		5.8	Within
                                            sixty (60) days after the end of each Quarter, the Licencee shall send to CRT a written
                                            statement detailing in respect of that Quarter (including a nil report if appropriate):

 

		5.8.1	any
                                            Milestone Events achieved by it or any Sub-Licencee and any Milestone Payments which became
                                            due to CRT;

 

		5.8.2	for
                                            each sub-licence, details of each item of Sub-Licence Revenue received by the Licencee during
                                            that Quarter and the Sub-Licence Revenue payable to CRT thereon;

 

		5.8.3	the
                                            quantity of each type of Licenced Product sold or otherwise disposed of by the Licencee or
                                            any Sub-Licencees or their Affiliates in each country in the Territory;

 

		5.8.4	the
                                            Net Sales in respect of each such type of Licenced Product in each country of the Territory;

 

		5.8.5	the
                                            aggregate Net Sales in respect of that Quarter for Licenced Product;

 

		5.8.6	the
                                            type and value of deductions made in the calculation of Net Sales by type of Licenced Product
                                            and country;

 

		5.8.7	subject
                                            to Clause 5.3, any currency conversions, showing the rates used;

 

		5.8.8	any
                                            further information necessary for the calculation of Sub-Licence Revenue and Net Sales of
                                            Licenced Products and/or the royalties due to CRT; and

 

		5.8.9	the
                                            amount of the royalties due to CRT in respect of that Quarter.

 

    14

     

    

 

CONFIDENTIAL

 

		5.9	The
                                            Licencee shall notify CRT in writing of the occurrence of any Milestone Event within sixty
                                            (60) days of the same if achieved by the Licencee and within sixty (60) days of
                                            becoming aware of the same if achieved by the Sub-Licencee.

 

		6.	ACCOUNTS

 

		6.1	The
                                            Licencee shall:

 

		6.1.1	keep
                                            and notwithstanding the expiry or termination of this Agreement, maintain and shall procure
                                            that each Sub-Licencee keeps and maintains, for at least three (3) years from the date
                                            to which such records relate, true and accurate accounts and records (including any underlying
                                            documents supporting such accounts and records) in sufficient detail to enable the amount
                                            of all sums payable under this Agreement to be determined; and

 

		6.1.2	during
                                            the Term and thereafter until the said period of three (3) years relevant to the accounts
                                            and records has expired, at the reasonable request of CRT, upon not less than thirty (30) days
                                            written notice, and (subject to Clause 6.2) at the expense of CRT from time to time
                                            but no more than once a year and once per set of records, permit or procure permission for
                                            a qualified accountant nominated by CRT, and reasonably acceptable to the Licencee (and that
                                            has entered into an appropriate confidentiality agreement with the Licencee) to inspect and
                                            audit those accounts and records. Subject to receiving not less than thirty (30) days
                                            written notice, the Licencee shall at the request of CRT assemble in one location all such
                                            relevant accounts and records of the Licencee and Sub-Licencees. Such accountant shall only
                                            report whether or not payments were properly paid in respect of that Quarter or Year under
                                            this Agreement and are accurate and shall provide its findings to both CRT and the Licencee
                                            and shall provide the Licencee a reasonable opportunity to respond.

 

		6.2	If,
                                            following any inspection pursuant to Clause 6.1.2, CRT’s nominated accountant
                                            confirms to CRT that the payments in respect of any Quarter or Year fall short of the sums
                                            which were properly payable in respect of that Quarter or Year under this Agreement, CRT
                                            shall send a copy of the certificate to the Licencee and the Licencee shall (subject to Clause 6.3)
                                            within thirty (30) days of the date of receipt of the certificate pay the shortfall
                                            to CRT and, if the shortfall exceeds [***], the Licencee shall also reimburse to CRT the
                                            reasonable costs and expenses of CRT in making the inspection.

 

		6.3	If
                                            within thirty (30) days of the date of receipt by the Licencee any certificate produced
                                            pursuant to Clause 6.2 the Licencee notifies CRT in writing that it disputes the certificate,
                                            the dispute shall be referred for resolution by the Expert in accordance with sub-Clause 25.1.

 

		7.	INTELLECTUAL
                                            PROPERTY MANAGEMENT

 

		7.1	All
                                            Patent Costs incurred after the Effective Date shall be met solely by the Licencee.

 

		7.2	The
                                            ownership of the Licenced Patents shall (as between the Parties) at all times remain vested
                                            solely in CRT.

 

		7.3	Subject
                                            to Clauses 7.4, 7.5 and 7.6, the Licencee shall be responsible for the Licenced Patents’
                                            IP Strategy in CRT’s sole name with the aim of maximising the duration and scope thereof.

 

		7.4	The
                                            Licencee shall discuss the Licenced Patents’ and Arising Patents’ IP Strategy
                                            with CRT and shall take into consideration all comments received from CRT in a timely manner
                                            in respect thereof.

 

		7.5	The
                                            Licencee shall keep CRT reasonably informed in writing as to the Licenced Patents’
                                            IP Strategy and shall promptly provide CRT with a copy of all submissions made to or responses
                                            received from the relevant patent offices and all correspondence to and responses received
                                            from the relevant patent agent in relation to the Licenced Patents in each applicable country
                                            of the Territory. The Licencee shall notify CRT at least three (3) months prior to any
                                            restriction of scope of any of the Licenced Patents.

 

    15

     

    

 

CONFIDENTIAL

 

		7.6	If
                                            the Licencee elects not to prosecute and/or maintain any part of the Licenced Patents, the
                                            Licencee shall notify CRT in writing at least three (3) months prior to the expiration
                                            of any applicable time bars. During the aforementioned three (3) months’ notice
                                            period, the Licencee shall retain the responsibility for the Licenced Patents’ IP Strategy
                                            in respect of the Licenced Patents identified in such notice. On the expiry of such notice
                                            period:

 

		7.6.1	the
                                            licence granted pursuant to Clause 2.1 shall terminate in respect of the Licenced Patents
                                            identified in such notice; and

 

		7.6.2	the
                                            Licencee shall, at CRT’s request, promptly transfer to CRT (or any person nominated
                                            by CRT) any and all documents and information in the Licencee’s control relating to
                                            such Licenced Patents; and

 

		7.6.3	CRT
                                            shall have the responsibility for the Licenced Patents’ IP Strategy in respect of the
                                            Licenced Patents identified in such notice, at its sole discretion and shall be free to grant
                                            rights thereunder to any person without further reference to the Licencee.

 

		7.7	The
                                            Licencee will notify CRT in writing promptly that any claim is made or threatened against
                                            the Licencee, a Sub-Licencee or an Affiliate of either of them by any person that the exercise
                                            by the Licencee, a Sub-Licencee or an Affiliate of either of them, of the rights granted
                                            pursuant to this Agreement infringe any patent or other rights of any Third Party.

 

		7.8	In
                                            the event of the circumstances described in Clause 7.7 arising, the Licencee shall use
                                            Commercially Reasonable Efforts to terminate such infringement or otherwise to remedy the
                                            position and shall report to CRT on the steps taken.

 

		7.9	Each
                                            Party will promptly notify the other Party in writing as soon as it becomes aware of any
                                            infringement or suspected infringement by a Third Party of any of the Licenced Patents or
                                            any unauthorised use of the Licenced Know How or the Licenced Materials.

 

		7.10	Provided
                                            the Licencee has a licence under this Agreement in relation to the relevant Licenced Patent
                                            and country (and where local law permits), within such country the Licencee may:

 

		7.10.1	at
                                            its own cost and subject to Clause 7.11, bring proceedings in its own name or, if required
                                            by law, jointly with CRT, for infringement of the Licenced Patents in the Field; and

 

		7.10.2	in
                                            any such proceedings settle any claim for infringement of the Licenced Patents in the Field,
                                            provided it obtains the prior written consent of CRT (which shall not be unreasonably withheld
                                            or delayed).

 

Any damages,
profits, and awards of whatever nature recovered by the Licencee for such infringement shall be treated as Net Sales subject to a deduction
for the Licencee’s reasonable external legal expenses insofar as these are not recovered from a third party. In any such proceedings,
CRT shall, at the Licencee’s cost, promptly provide the Licencee with all documents and assistance as the Licencee may reasonably
require. The Licencee shall promptly provide CRT with notice of such proceedings and keep CRT regularly informed of progress and promptly
provide CRT with such information as CRT may require including copies of all documents filed at court in the proceedings. If CRT is joined
to proceedings pursuant to Clause 7.10.1 or otherwise, the Licencee shall indemnify and hold harmless CRT, the Charity any university
or academic research institute from which Licenced Intellectual Property arises and their respective officers, directors, employees and
agents and the inventors named in any Licenced Patents (the “CRT Indemnities”) from and against any and all claims,
demands, losses, causes of action, damages and expenses (including without limitation, legal fees) arising from or in connection with
such proceedings.

 

    16

     

    

 

CONFIDENTIAL

 

		7.11	Prior
                                            to commencing any proceedings pursuant to Clause 7.10, the Licencee shall (or shall
                                            procure that its Sub-Licencee shall) enter into a separate agreement with CRT pursuant to
                                            which the Licencee (or the Sub-Licencee if applicable) shall indemnify the CRT Indemnitees
                                            in respect of any and all potential Third Party claims, demands, losses, damages, costs and
                                            expenses (including, without limitation, legal fees) which might arise directly or indirectly
                                            as a consequence of such proceedings being concluded successfully or unsuccessfully (including
                                            without limitation any anti-trust proceedings commenced by a Third Party (for example, alleging
                                            that the price of any Licenced Product has been kept artificially high through the maintenance
                                            of Patent Rights which are invalid and/or unenforceable for any reason)).

 

		7.12	If
                                            the Licencee does not exercise its right to bring proceedings pursuant to Clause 7.10
                                            within sixty (60) days of the written notification pursuant to Clause 7.9 or such
                                            longer period as may be agreed by the Parties then CRT shall be entitled, but not obliged
                                            to bring such proceedings at its own cost. If necessary, (including to recover damages),
                                            the Licencee shall join in such proceedings. Any monies recovered in such proceedings shall
                                            first be used to reimburse the Parties for any costs incurred and the remainder shall be
                                            allocated [***]. In any such proceedings the Licencee shall promptly provide CRT with all
                                            documents and assistance as CRT may reasonably require and CRT shall promptly provide the
                                            Licencee with notice of such proceedings.

 

		7.13	The
                                            Parties shall, at the request of either of them and at the expense of the requesting Party
                                            but for no further consideration, enter into such confirmatory patent licences relating to
                                            the Licenced Patents, substantially in the form set out in Schedule 4, as may be necessary
                                            or desirable in accordance with the relevant law and practice in each country in the Territory
                                            for registration at the relevant patent offices so that this Agreement need not be registered
                                            or recorded unless the Parties are required to do so by law. If there are any inconsistencies
                                            between the terms of any such confirmatory patent licence and the provisions of this Agreement,
                                            this Agreement shall prevail.

 

		7.14	With
                                            respect to each Licenced Product, the Licencee shall, to the extent consistent with Commercially
                                            Reasonable Efforts, at the time of receipt of the relevant Regulatory Approval, or such other
                                            time as appropriate, apply for a Supplementary Protection Certificate, patent term extension
                                            and/or any other exclusivity in respect of such Licenced Product. At the Licencee’s
                                            reasonable request and sole cost, CRT will provide reasonable assistance to the Licencee
                                            in connection with any such applications.

 

		8.	WARRANTY

 

		8.1	CRT
                                            warrants to the Licencee that:

 

		8.1.1	it
                                            has the legal capacity to enter into this Agreement;

 

		8.1.2	at
                                            the Effective Date, it is the legal, beneficial and registered owner of the Licenced Patents;

 

		8.1.3	it
                                            has not and will not enter into any agreement which prevents it from fulfilling its obligations
                                            under, or is otherwise inconsistent with, this Agreement;

 

		8.1.4	it
                                            has complied and shall comply with the Bribery Act 2010 in connection with the Agreement;
                                            and

 

		8.1.5	no
                                            claim has been issued and served, or written threat of a claim or litigation made by any
                                            person, against CRT that alleges the Licenced Patents are invalid or unenforceable, and CRT
                                            has not issued a claim against a Third Party alleging, or alleged in writing, that a Third
                                            Party is infringing or has infringed or misappropriated the Licenced Patents or the Licenced
                                            Know How.

 

    17

     

    

 

CONFIDENTIAL

 

		8.2	The
                                            Licencee warrants to CRT that:

 

		8.2.1	it
                                            has the legal capacity to enter into this Agreement.

 

		8.3	Each
                                            Party acknowledges that, in entering into this Agreement, it does not do so in reliance on
                                            any warranty or other provision except as expressly provided in this Agreement, and all conditions,
                                            warranties, terms and undertakings implied by statute, common law or otherwise are excluded
                                            from this Agreement to the fullest extent permissible by law.

 

		8.4	Without
                                            limiting the scope of Clause 8.3, save as expressly set out at Clause 8.1, CRT
                                            does not give any warranty, representation or undertaking in relation to the Licenced Intellectual
                                            Property, including any warranty, representation or undertaking:

 

		8.4.1	as
                                            to the efficacy, usefulness, completeness or accuracy of the Licenced Intellectual Property;
                                            or

 

		8.4.2	that
                                            it owns all necessary property and other rights in the Licenced Intellectual Property; or

 

		8.4.3	that
                                            any of the Licenced Patents is or will be valid or subsisting or that any of the applications
                                            within the Licenced Patents will proceed to grant; or

 

		8.4.4	that
                                            the use of any Licenced Intellectual Property, including without limitation any invention
                                            claimed in a Licenced Patent, or the exercise of any rights granted under this Agreement
                                            will not infringe the intellectual property or other rights of any other person.

 

		8.5	CRT’s
                                            aggregate liability for breach of one or more of the warranties in this Clause 8 shall
                                            be limited to [***].

 

		9.	INDEMNITY

 

		9.1	The
                                            Licencee shall indemnify, defend and hold harmless Indemnified Parties from and against any
                                            and all third party claims, demands, losses, damages, costs and expenses (including reasonable
                                            legal fees) arising from or in connection with the exercise by the Licencee or a Sub-Licencee
                                            of the rights granted in Clause 2.1 or the actions of the Licencee, a Sub-Licencee or
                                            an Affiliate of either of them in relation to a Licenced Product, except to the extent any
                                            such claims, demands, losses, damages and expenses arise from the negligent or wilful actions
                                            or inactions of misconduct by any Indemnified Party.

 

		9.2	Promptly
                                            after receipt by CRT of any claim or alleged claim or notice of the commencement of any action,
                                            administrative or legal proceeding, or investigation to which the indemnity provided for
                                            in this Clause 9 may apply, CRT shall give written notice to the Licencee of such fact
                                            and the Licencee shall have the option to assume the defence thereof by election in writing
                                            within thirty (30) days of receipt of CRT’s notice. If the Licencee fails to make
                                            such election, the Indemnified Party may assume such defence and the Licencee will be liable
                                            for the reasonable legal and other expenses consequently incurred in connection with such
                                            defence. The Parties will co-operate in good faith in the conduct of any defence, will provide
                                            such reasonable assistance as may be required to enable any claim to be defended properly
                                            and the Party with conduct of the action shall promptly provide to the other Party copies
                                            of all correspondence and documents and notice in writing of the substance of all oral communications
                                            relating to such action.

 

		9.3	Should
                                            the Licencee assume conduct of the defence:

 

    18

     

    

 

CONFIDENTIAL

 

		9.3.1	the
                                            Indemnified Party may retain separate legal advisers, at its sole cost and expense save that
                                            if the Licencee denies the applicability of the indemnity or reserves its position in relation
                                            to the same, the indemnity in this Clause 9 shall extend to the Indemnified Party’s
                                            costs and expenses so incurred; and

 

		9.3.2	the
                                            Licencee will not, except with the written consent of the Indemnified Party, such consent
                                            not to be unreasonably withheld, conditions or delayed, consent to the entry of any judgment
                                            or enter into any settlement provided always, that if the Indemnified Party shall not consent
                                            to such entry of judgment or settlement, the amount which the Indemnified Party shall be
                                            entitled to recover from the Licencee pursuant to this Clause 9 shall be limited to
                                            the amount for which the action would otherwise have been settled or compromised; and

 

		9.3.3	CRT
                                            and any other Indemnified Party shall not admit liability in respect of, or compromise or
                                            settle any such action without the prior written consent of the Licencee, such consent not
                                            to be unreasonably withheld, conditioned or delayed; and

 

		9.3.4	Licencee
                                            shall not be responsible for or bound by any settlement made by CRT in breach of Clause 9.3.3,
                                            provided, that,

 

		9.3.5	Notwithstanding
                                            the foregoing, the Licencee may, without the consent of the Indemnified Party, settle a third
                                            party claim solely to the extent such settlement is strictly monetary in nature, places no
                                            further obligations or penalties on the Indemnified Parties and the Licencee includes a release
                                            in the settlement agreement to absolve the Indemnified Parties from any and all liabilities
                                            arising out of the settled claims.

 

		10.	INSURANCE

 

		10.1	Reasonably
                                            prior to Commencement of a Phase I Trial, the Licencee shall put in place and thereafter
                                            maintain, at its own cost, comprehensive product liability insurance and general commercial
                                            liability insurance through a reputable insurance company. At CRT’s request, the Licencee
                                            shall: (i) ensure that CRT’s interest as co-assured be noted on the policy or
                                            policies; and (ii) provide CRT with a certificate evidencing the coverage required hereby,
                                            and the amount thereof and the noting of CRT’s interest. Such insurance shall be maintained
                                            for not less than three (3) years following the expiration or termination of this Agreement
                                            for any reason or if such coverage is of the “claims made” type, for five (5) years
                                            following the expiration or termination of this Agreement for any reason.

 

		11.	LIMITATION
                                            OF LIABILITY

 

		11.1	Subject
                                            to Clause 11.3, neither Party, nor the Charity nor any collaborating academic institutions
                                            nor their respective directors, officers, employees and agents shall have any liability under
                                            or in connection with this Agreement whether under statute or in tort (including negligence),
                                            contract or otherwise in respect of: (i) any consequential or indirect loss; and/or
                                            (ii) any loss of goodwill, opportunity, profit or contract, in either case even if advised
                                            in advance of the possibility of such losses.

 

		11.2	Subject
                                            to Clauses 8.5 and 11.3, in no event shall the liability of CRT under this Agreement
                                            exceed [***] in aggregate for any and all claims.

 

		11.3	Nothing
                                            in this Agreement shall be construed as excluding or limiting the liability of any person
                                            for any liability which cannot be limited or excluded by law.

 

    19

     

    

 

CONFIDENTIAL 

 

		12.	CONFIDENTIALITY

 

		12.1	Each
                                            Party (the “Receiving Party”) undertakes to the other Party (the “Disclosing
                                            Party”) that it shall keep, and it shall procure that its and its Affiliates’
                                            respective directors, officers, employees and agents, and CRT Reviewers (collectively, “Representatives”)
                                            shall keep, secret and confidential all Confidential Information of the Disclosing Party
                                            and shall not publish or disclose the same or any part of the same to any person whatsoever
                                            other than:

 

		12.1.1	in
                                            the case of the Licencee to: (i) Sub-Licencees and Third Party Service Providers, subject
                                            to compliance with Clauses 2.4.4 and 16.3 respectively; (ii) Competent Authorities
                                            in the Territory as necessary in communications relating to the Licenced Products; and (iii) potential
                                            Sub-Licencees, potential Third Party Service Providers, potential and actual investors or
                                            acquirers, and advisors provided that any such persons have agreed to be bound by a legal
                                            obligation of confidentiality no less restrictive than that set forth in this Clause 12
                                            and any disclosure or use of Confidential Information by any such person which would constitute
                                            a breach of this Agreement if done by the Licencee will be deemed to be a breach of this
                                            Agreement by the Licencee, who will be liable to CRT accordingly;

 

		12.1.2	in
                                            the case of each Party, to its Representatives directly or indirectly concerned in the exercise
                                            of the rights granted under this Agreement; and

 

		12.1.3	in
                                            the case of CRT, to CRT Reviewers.

 

		12.2	Each
                                            Party shall ensure that each of its Representatives to whom any Confidential Information
                                            is disclosed shall previously have been informed of the confidential nature of the Confidential
                                            Information and shall have agreed to be bound by a legal obligation of confidentiality no
                                            less restrictive than that set forth in this Clause 12.

 

		12.3	The
                                            provisions of Clauses 12.1, 12.2 and 12.3 shall not apply to Confidential Information
                                            which the Receiving Party can demonstrate by reference to written records to have come into
                                            its possession other than under an obligation of confidence to the Disclosing Party or to
                                            a third party;

 

		12.3.1	enters
                                            the public domain otherwise than through a breach of any obligation of confidentiality owed
                                            to the Disclosing Party; or

 

		12.3.2	the
                                            Receiving Party can prove it has independently developed without direct or indirect access
                                            to any of the Disclosing Party’s Confidential Information.

 

		12.4	The
                                            Receiving Party may disclose Confidential Information to the extent that such disclosure
                                            is:

 

		12.4.1	necessarily
                                            required of the Receiving Party by order of a Competent Authority or otherwise by applicable
                                            law; provided, that the Receiving Party shall, to the extent practicable, first have given
                                            notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to
                                            quash any such order or obtain a protective order requiring that the Confidential Information
                                            the subject of such order be held in confidence by such Competent Authority or, if disclosed,
                                            be used only for the purpose for which the order was issued; and provided further that if
                                            such order is not quashed or a protective order is not obtained, the Confidential Information
                                            disclosed in response to such order shall be limited to that information that is legally
                                            required to be disclosed in response to such order;

 

		12.4.2	made
                                            by the Receiving Party to a patent or regulatory authority as may be necessary or useful
                                            for the purposes of obtaining or enforcing a Licenced Patent (consistent with the terms and
                                            conditions of Clause 7) or obtaining or maintaining a Regulatory Authorisation, provided,
                                            however, that reasonable measures shall be taken to assure confidential treatment of such
                                            information, to the extent such protection is available; or

 

    20

     

    

 

CONFIDENTIAL

  

		12.4.3	required
                                            with regard to the disclosure requirements of a national securities exchange or other stock
                                            market or of a related regulatory body on which the Receiving Party’s securities are
                                            or are proposed to be traded, provided, however, that reasonable measures shall be taken
                                            to assure confidential treatment of such information, to the extent such protection is available.

 

		12.5	Insofar
                                            as the Receiving Party believes that any of the provisions of Clause 12.3.1, 12.3.2
                                            or 12.3.3 apply to Confidential Information, it shall notify the Disclosing Party at the
                                            earliest opportunity.

 

		12.6	The
                                            Receiving Party agrees that the disclosure of the Disclosing Party’s Confidential Information
                                            without the express written consent of the Disclosing Party may cause irreparable harm to
                                            the Disclosing Party, and that any breach or threatened breach of this Agreement by the Receiving
                                            Party may entitle the Disclosing Party to injunctive relief, in addition to any other legal
                                            remedies available to it, in any court of competent jurisdiction.

 

		12.7	The
                                            provisions of this Clause 12 shall remain in force for a period of ten (10) years
                                            from the expiry or termination of this Agreement.

 

		13.	TERM
                                            AND TERMINATION

 

		13.1	This
                                            Agreement will become effective on the Effective Date. Subject to the provisions of this
                                            Clause 13 it will remain effective, on a Licenced Product-by-Licenced Product, in each
                                            country of the Territory until expiry of the obligation upon the Licencee to pay royalties
                                            in relation to that country and Licenced Product pursuant to Clause 4.5 and 4.6 of this
                                            Agreement. Upon expiration of this Agreement with respect a given Licenced Product and country,
                                            (i) the Licence granted to the Licencee hereunder with respect to such Licenced Product
                                            and country shall become fully paid-up, perpetual and irrevocable, and (ii) Net Sales
                                            associated with such Licenced Product and country shall no longer be considered for purposes
                                            of calculating royalty tiers or commercial milestones.

 

		13.2	Without
                                            prejudice to any other rights of the Parties, this Agreement may be terminated by notice
                                            in writing:

 

		13.2.1	by
                                            either Party forthwith if the other Party is in material breach of this Agreement and fails
                                            to remedy the breach within ninety (90) Business Days of written notice containing full
                                            particulars of the breach and requiring it to be remedied; provided, that, if such breach
                                            only affects either the Topical Licenced Product or the Non-Topical Licenced Product, then
                                            termination pursuant to this Clause 13.2.1 shall only be with respect to the affected
                                            Licenced Product and this Agreement shall remain in full force and effect with respect to
                                            the other Licenced Product (and the effects of termination shall be applied accordingly);
                                            or

 

		13.2.2	by
                                            the Licencee on thirty (30) days written notice to CRT; or

 

		13.2.3	by
                                            CRT forthwith if a voluntary arrangement is proposed or approved or an administration order
                                            is made, or a receiver or administrative receiver is appointed of any of the Licencee’s
                                            assets or undertakings or a winding-up resolution or petition is passed (otherwise than for
                                            the purpose of solvent reconstruction or amalgamation) or if any circumstances arise which
                                            entitle a court or a creditor to appoint a receiver, administrative receiver or administrator
                                            or make a winding-up order or similar or equivalent action is taken against or by the Licencee
                                            by reason of its insolvency or in consequence of debt or if it appears in the reasonable
                                            opinion of CRT that the Licencee has ceased, or is likely to cease, trading, and the foregoing
                                            action is not retracted or withdrawn within sixty (60) days; or

 

    21

     

    

 

CONFIDENTIAL

  

	 	13.2.4	by CRT upon sixty (60) days
    written notice to the Licencee, if the Licencee, a Sub-Licencee or an Affiliate of either of them challenges the validity of any
    of the Licenced Patents and does not cease such challenge during such sixty (60) day notice period; provided, that if a Sub-Licencee
    undertakes such an action and the Licencee terminates the relevant sub-Licence agreement, then CRT shall not be permitted to terminate
    this Agreement in connection with such challenge; or

 

	 	13.2.5	by CRT forthwith in the event
of a change of Control of the Licencee where the new Controlling party is a Tobacco Party; or

 

	 	13.2.6	by CRT upon forty-five (45) days
written notice to the Licencee if the Licencee:

 

	 	(a)	discontinues the development
(including prosecuting application for Regulatory Authorisation) of all Licenced Products and no Licenced Product is being commercialized;
or

 

	 	(b)	having obtained Regulatory
Authorisation for Licenced Product in some or all of the Major Markets, ceases to use best efforts to actively market and sell all Licenced
Product under such Regulatory Authorisation; or

 

	 	(c)	ceases to carry on business
in the Field; or

 

	 	(d)	fails to raise all monies pursuant
to Clause 3.5, 13.2.7 in accordance with Clause 3.6.

 

	 	13.3	Without prejudice to any other
rights of the Parties, if the Licencee fails to comply with the performance obligations pursuant to Clause 3.1 and Clause 3.5
in relation to the development and commercialisation of Topical Licenced Products or Non-Topical Licenced Products, the licence granted
pursuant to Clause 2.1 to develop and commercialise Topical Licenced Products or Non-Topical Licenced Products may be terminated
by CRT upon thirty (30) days written notice (to be given in CRT’s sole discretion) in writing to the Licencee, and in accordance
with Clause 3.6. For the avoidance of doubt, in the event of any conflict or ambiguity between the provisions of Clause 13.2.1
and this Clause 13.3, the provisions of this Clause 13.3 shall take control and precedence.

 

	 	14.	EFFECTS OF TERMINATION

 

	 	14.1	Upon the termination of this
Agreement in its entirety for any reason or upon the termination of the Licence pursuant to Clause 13.2 for any reason:

 

	 	14.1.1	payment of royalties and all
other sums due to CRT shall become payable to CRT immediately upon notice of termination of this Agreement;

 

	 	14.1.2	the Licencee shall, within
thirty (30) days of notice of termination of this Agreement provide CRT with a final written statement detailing, in respect of
the time elapsed since the last report under Clause 5.8, the matters set out in Clause 5.8;

 

	 	14.1.3	the Licencee shall consent
to the revocation of any confirmatory patent licence relating to the Licenced Patents granted pursuant to Clause 7.13 and the cancellation
of the registration of any such licence in any register;

 

	 	14.1.4	the Licencee shall promptly
transfer to CRT (or any person nominated by CRT), at CRT’s reasonable expense, any and all documents and information in the Licencee’s
control or possession relating to the Licenced Patents and CRT may assume responsibility for the Licenced Patents’ IP Strategy;

 

    22

     

    

 

CONFIDENTIAL

  

	 	14.1.5	the licences granted to the
Licencee pursuant to Clause 2 shall terminate forthwith and the Licencee shall (and shall procure that its Sub-Licencees and Affiliates
shall) immediately cease to exploit the Licenced Intellectual Property in any way, either directly or indirectly, except as necessary
to perform its obligations under this Clause 14.1;

 

		14.1.6	the
                                            Licencee shall have the right to sell any inventory of Licenced Product for a period of twelve
                                            (12) months (and subject to all applicable obligations under this Agreement) and thereafter
                                            shall, at the request of CRT and option of Licencee, transfer to CRT such quantities of Licenced
                                            Product and Licenced Materials as is in the Licencee’s control ;

 

	 	14.1.7	in the event that CRT desires
to proceed with the development and/or exploitation of any Licenced Products it shall provide written notice thereof to Licencee and:

 

	 	(a)	the Licencee hereby grants
to CRT a perpetual, irrevocable, sub-licensable, worldwide licence to research, develop, make, have made, market, use and sell Licenced
Products falling within the scope of the Arising Intellectual Property. Such licence shall be exclusive in respect of any Arising Intellectual
Property that specifically relates to Licenced Products (“Exclusive Arising Intellectual Property”) and otherwise
non-exclusive;

 

	 	(b)	CRT shall be solely responsible
for the Arising Patents’ IP Strategy and Arising Patents’ Patent Costs of all Arising Patents comprised within the Exclusive
Arising Intellectual Property (CRT shall be entitled to treat all such expenses as Expenses);

 

		(c)	the
                                            Licencee shall, at CRT’s request, transfer to CRT (or its nominee) as soon as practicable
                                            any Regulatory Authorisations, Price Approvals and other permits and applications relating
                                            to Licenced Products;

 

		(d)	the
                                            Licencee shall within one (1) month of the date of termination of this Agreement transfer
                                            to CRT (or CRT’s nominee) all Exclusive Arising Intellectual Property, and copies of
                                            all any documents and information within the Licencee’s control relating to the filing
                                            and prosecution of any Patents comprised in Exclusive Arising Intellectual Property; and

 

		(e)	the
                                            Licencee shall be entitled to receive a share of any Net Revenue to be negotiated in good
                                            faith between the Parties. Such share shall be determined having regard to the development
                                            stage which the Licencee (or its Sub-Licencee) has reached at the date of termination in
                                            respect of the Licenced Product.

 

		14.2	Upon
                                            the termination of a licence pursuant to Clause 13.3 for any reason:

 

		14.2.1	the
                                            Licencee hereby grants to CRT an exclusive perpetual, irrevocable, sub-licensable, worldwide
                                            licence to research, develop, make, have made, market, use and sell Topical Licenced Products
                                            or Non-Topical Licenced Products falling within the scope of the Exclusive Arising Intellectual
                                            Property and otherwise non-exclusive;

 

		14.2.2	CRT
                                            shall be solely responsible for the Licenced Patents’ IP Strategy related to Topical
                                            Licenced Products or Non-Topical Licenced Products;

 

    23

     

    

 

CONFIDENTIAL

  

		14.2.3	the
                                            Licencee shall discuss the Arising Patents’ IP Strategy related to Topical Licenced
                                            Products or Non-Topical Licenced Products with CRT and shall take into consideration all
                                            comments received from CRT in respect thereof;

 

		14.2.4	if
                                            subsequently CRT enters into a licence with a Third Party to commercialise the Licenced Patents
                                            and/or Arising Patents related to Topical Licenced Products or Non-Topical Licenced Products,
                                            the Parties will meet to discuss reimbursement of Patent Costs on a pro rata basis.

 

		14.2.5	if
                                            subsequently CRT enters into a licence with a Third Party to commercialise the Licenced Patents
                                            and/or Arising Patents related to Topical Licenced Products or Non-Topical Licenced Products,
                                            the Licencee shall be entitled to receive a share of any Net Revenue to be negotiated in
                                            good faith between the Parties. Such share shall be determined having regard to the development
                                            stage which the Licencee (or its Sub-Licencee) has reached at the date of termination in
                                            respect of the Topical Licenced Products or Non-Topical Licenced Products.

 

		14.3	The
                                            termination of this Agreement howsoever arising or termination of the Licence pursuant to
                                            any of the provisions of Clause 13 will be without prejudice to the rights and duties
                                            of either Party accrued prior to termination. The following Clauses will continue to be enforceable
                                            notwithstanding termination: Clauses 1, 2.3, 2.4.1, 6, 7.11, 9, 10, 11, 12, 14 and 17
                                            to 26 inclusive.

 

		15.	FORCE
                                            MAJEURE

 

		15.1	If
                                            a Party is unable to carry out any of its obligations under this Agreement due to Force Majeure
                                            (the “Non-Performing Party”) this Agreement shall remain in effect but
                                            the Non-Performing Party’s relevant obligations under this agreement and the relevant
                                            obligations of the other Party (“the Innocent Party”) under this Agreement
                                            shall be suspended for the duration of the circumstance of Force Majeure provided that:

 

		15.1.1	the
                                            suspension of performance is of no greater scope than is required by the Force Majeure;

 

		15.1.2	the
                                            Non-Performing Party gives the Innocent Party prompt notice describing the circumstance of
                                            Force Majeure, including the nature of the occurrence and its expected duration, and continues
                                            to furnish regular reports during the period of Force Majeure;

 

		15.1.3	the
                                            Non-Performing Party uses all reasonable efforts to remedy its inability to perform and to
                                            mitigate the effects of the circumstance of Force Majeure; and

 

		15.1.4	as
                                            soon as practicable after the event which constitutes Force Majeure the Parties shall discuss
                                            how best to continue their operations as far as possible in accordance with this Agreement.

 

		15.2	If
                                            the Force Majeure continues for three (3) months or more, the Innocent Party may give
                                            twenty (20) Business Days written notice to terminate this Agreement to the Non-Performing
                                            Party and termination shall occur if the Force Majeure is continuing at the end of that twenty
                                            (20) Business Day notice period.

 

		16.	ASSIGNMENT
                                            AND SUB-CONTRACTING

 

		16.1	This
                                            Agreement shall be binding upon and inure to the benefit of the Parties, their successors
                                            and assigns.

 

		16.2	Either
                                            Party may assign this Agreement, in whole or in part:

 

    24

     

    

 

CONFIDENTIAL

  

		16.2.1	with
                                            the written consent of the other; or

 

		16.2.2	without
                                            the consent of the other Party, in whole, to any third party successor to all or substantially
                                            all of the assets of its business to which this Agreement relates whether by merger, sale
                                            of stock of assets, operation of law or otherwise;

 

		16.2.3	provided
                                            that any such successor is not a Tobacco Party.

 

		16.3	The
                                            benefit of this Agreement (but, for the avoidance of doubt, not the burden) shall be assignable
                                            by CRT in connection with a transaction with an assignee concerning CRT’s income arising
                                            under this Agreement.

 

		16.4	The
                                            Licencee may not sub-contract its obligations under this Agreement to any person other than
                                            an Affiliate of the Licencee or a Third Party Service Provider. The Licencee shall ensure
                                            that an appropriate written agreement is put in place with each Third Party Service Provider.
                                            Any act or omission of an Affiliate of the Licencee or a Third Party Service Provider which,
                                            if it were the act or omission of the Licencee would be a breach of any of the provisions
                                            of this Agreement, will be deemed to be a breach of this Agreement by the Licencee who will
                                            be liable to CRT accordingly.

 

		17.	NOTICES

 

		17.1	All
                                            notices shall be in writing and sent by hand, facsimile, or recorded delivery and shall be
                                            deemed to be properly served (i) if sent by hand, when delivered at the relevant address;
                                            (ii) if sent by recorded delivery, five (5) Business Days after posting; (iii) if
                                            sent by facsimile or email when transmitted, provided a confirmatory copy is sent by post
                                            within twenty four (24) hours of transmission, and shall be sent to the following addresses
                                            or facsimile numbers or emails as may be amended by the relevant Party in writing:

 

[***]

 

		18.	VARIATION

 

		18.1	No
                                            variation, modification, amendment, extension or release from any provision of this Agreement
                                            shall be effective unless it is in writing, signed by both Parties.

 

		19.	ENTIRE
                                            AGREEMENT

 

		19.1	Each
                                            Party confirms that this Agreement (including all Schedules) represents the entire understanding,
                                            and constitutes the whole agreement, in relation to its subject matter and supersedes any
                                            previous agreement between the Parties with respect thereto.

 

		19.2	Each
                                            Party confirms that:

 

		19.2.1	in
                                            entering into this Agreement it has not relied on any representation or warranty or undertaking
                                            which is not contained in this Agreement; and

 

		19.2.2	in
                                            any event, without prejudice to any liability for fraudulent misrepresentation or fraudulent
                                            misstatement, neither Party shall be under any liability or shall have any remedy in respect
                                            of misrepresentation or untrue statement unless and to the extent that a claim lies under
                                            this Agreement.

 

		20.	FURTHER
                                            ASSURANCE

 

		20.1	Each
                                            Party hereby undertakes to do all such other acts and things, and execute and provide all
                                            such documents at the other Party’s request and cost as may be necessary or desirable
                                            to give effect to the purposes of this Agreement.

 

    25

     

    

 

CONFIDENTIAL

  

		21.	WAIVER

 

		21.1	No
                                            relaxation, forbearance, waiver or indulgence by either Party in enforcing any of the terms
                                            or conditions of this Agreement or the granting of time by either Party to the other shall
                                            prejudice, affect or restrict the rights and powers of such Party, unless contained in a
                                            writing signed by the Party charged with such waiver. The waiver of any breach of any term
                                            or any condition of this Agreement shall not be construed as a waiver of any subsequent breach
                                            of a term or condition of the same or of a different nature.

 

		22.	SEVERABILITY

 

		22.1	If
                                            the whole or any part of this Agreement is or becomes or is declared illegal, invalid or
                                            unenforceable in any jurisdiction for any reason (including by reason of the provisions of
                                            any legislation and/or by reason of any court or Competent Authority):

 

		22.1.1	in
                                            the case of the illegality, invalidity or unenforceability of the whole of this Agreement
                                            it shall terminate only in relation to the jurisdiction in question; or

 

		22.1.2	in
                                            the case of the illegality, invalidity or unenforceability of a part of this Agreement that
                                            part shall be severed from this Agreement in the jurisdiction in question and that illegality,
                                            invalidity or unenforceability shall not in any way whatsoever prejudice or affect the remaining
                                            parts of this Agreement which shall continue in full force and effect and in no circumstances
                                            shall sums paid by the Licencee to CRT under this Agreement be repayable.

 

		22.2	If
                                            in the reasonable opinion of either Party any severance under this Clause 22 materially
                                            affects the commercial basis of this Agreement, the Parties shall discuss, in good faith,
                                            ways to eliminate the material effect.

 

		23.	EXECUTION

 

		23.1	This
                                            Agreement may be executed in any one or more number of counterpart agreements each of which,
                                            when executed, shall be deemed to form part of and together constitute this Agreement.

 

		24.	ANNOUNCEMENTS
                                            AND USE OF NAMES

 

		24.1	Save
                                            as provided in Clause 24.2 neither Party shall make, or procure or permit the making
                                            of, any form of advertising, press release or other public announcement (including any promotion
                                            or publicity on any website or in any company publication) in relation to this Agreement
                                            without first obtaining the written approval of the other Party to any such release or announcement.

 

		24.2	Any
                                            Party may make an announcement with respect to this Agreement or any ancillary matter if
                                            required by law or the regulations of any stock exchange to which it is subject, without
                                            the other Party’s consent provided it has used reasonable endeavours in the time available
                                            to consult with the other Party on the terms of any such announcement beforehand.

 

		24.3	Neither
                                            Party shall use the name, logo or marks of the other (including in the case where the other
                                            is CRT, that of the Charity (or its successor)) other than as provided in Clause 24.1
                                            and 24.2 without the prior written consent of that Party which shall be at that Party’s
                                            sole discretion.

 

		25.	DISPUTE
                                            RESOLUTION AND GOVERNING LAW

 

		25.1	In
                                            the event that a determination of the Expert is sought under this Agreement:

 

		25.1.1	the
                                            opinion of that Expert (who shall act as an expert and not as an arbitrator) shall be final
                                            and binding on the Parties;

 

    26

     

    

 

CONFIDENTIAL

  

		25.1.2	each
                                            Party shall make written submissions to the Expert and to the other Party within sixty (60) Business
                                            Days of the Expert’s appointment;

 

		25.1.3	each
                                            Party shall have thirty (30) Business Days to respond to the other Party’s submissions;

 

		25.1.4	the
                                            Parties shall request that the Expert deliver his opinion within a further thirty (30) Business
                                            Days; and

 

		25.1.5	the
                                            costs associated with the appointment of the Expert shall be borne in such proportions as
                                            the Expert may determine to be fair and reasonable in all the circumstances or, if no such
                                            determination is made by the Expert, by the Parties in equal proportions.

 

		25.2	It
                                            shall be a condition precedent to the commencement of any action in court or other tribunal
                                            (save an action for an interim injunction) in respect of any dispute relating to this Agreement
                                            that the Parties have sought to resolve the dispute by either Party notifying the other Party
                                            in writing for resolution to the Executive Officers who shall meet (whether in person or
                                            via teleconference) within sixty (60) days of such notice to seek resolution in good
                                            faith. If the Executive Officers are unable to resolve the dispute at such meeting, either
                                            Party may pursue any remedy available to such Party at law or in equity, subject to the terms
                                            and conditions of this Agreement.

 

		25.3	This
                                            Agreement shall be governed by and construed in accordance with the laws of England and Wales
                                            and the Parties agree, subject to Clauses 25.1 and 25.2, to submit to the exclusive
                                            jurisdiction of the English courts in respect of any dispute arising out of or in connection
                                            with this Agreement (except in respect of disputes under Clause 12 where jurisdiction
                                            is non-exclusive).

 

		26.	CONTRACTS
                                            (RIGHTS OF THIRD PARTIES) ACT 1999

 

		26.1	Save
                                            that the Charity may enforce Clauses 9.1, 11.1 and 24.3, and the Charity and CRT Indemnities
                                            and their respective officers, employees and agents may enforce Clauses 9.1 and 11.1,
                                            no term of this Agreement is enforceable under the Contracts (Rights of Third Parties) Act
                                            1999 by a person who is not a party to this Agreement. Notwithstanding the provisions of
                                            this Clause 26, the Parties shall be entitled to amend, suspend, cancel or terminate
                                            this Agreement or any part of it in accordance with Clause 18, without the consent of
                                            any Third Party including those referred to in this Clause 26.

 

    27

     

    

 

CONFIDENTIAL

 

The Parties hereby
execute this Agreement by their duly authorised representatives:

 

For CANCER RESEARCH
TECHNOLOGY LIMITED

Signature:________________________________________

Name:__________________________________________

Title:____________________________________________

 

For Varian Biopharma
LLC

Signature:________________________________________

 

Name:___________________________________________

Title:___________________________________________

 

    28

     

    

 

CONFIDENTIAL

 

SCHEDULE 1

LICENCED PATENTS

 

[***]

 

    1

     

    

 

CONFIDENTIAL

 

SCHEDULE 2

LICENCED KNOW HOW

 

 [***]

 

    1

     

    

 

CONFIDENTIAL

 

SCHEDULE 3

LICENCED MATERIALS

 

[***]

 

    1

     

    

 

CONFIDENTIAL

 

SCHEDULE 4

CONFIRMATORY PATENT LICENCE

 

[***]

 

    2

     

    

 

CONFIDENTIAL

 

Schedule 5

Development plan

 

[***]

    1

     

    

 

CONFIDENTIAL 

 

SCHEDULE 6

FUNDRAISING PLAN

[***]

  1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]